Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.
Sanofi meets estimates for fourth-quarter profit
French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The drugmaker reported steady growth across its key therapeutic areas and highlighted strong performance from new product launches.
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.
Sanofi plans 5 billion euro buyback, sees higher profit growth
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs such as its respiratory syncytial virus (RSV) shot.
Sanofi reports Q4 IRFS EPS EUR 0.54
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with ...
PharmiWeb4h
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with ...
Sanofi board proposed dividend of EUR 3.92 for FY24
The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...
Sanofi: Q4 Earnings Snapshot
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for ...
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
PMLiVE2h
Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma
Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
Analysts Offer Insights on Healthcare Companies: Sumitomo Dainippon Pharma Co (OtherDNPUF) and Sanofi (OtherSNYNF)
Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...